



14<sup>th</sup> December, 2021

# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Corporate Relationship Department  
The BSE Ltd.  
Dalal Street, Fort  
Mumbai – 400 001.

The Manager – Listing  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra-Kurla Complex  
Bandra(E), MUMBAI – 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:


Sl. No.	Particulars
1.	<p>The Board of Directors have approved to acquire M/s. Dash Pharmaceuticals LLC, USA through one of its subsidiary Company.</p> <p>The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure - I.</p>
2.	<p>Allotted 27,340 equity shares of Rs.2/- each to the eligible employees who had exercised their vested options under Company's Natco Employees Stock Option Scheme (NATSOP 2016). The said equity shares shall rank parri-passu with the existing equity shares of the Company in all respects including dividends and corporate benefits, if any, declared by the Company.</p> <p>Resultantly, the paid-up share capital of the Company will be Rs.36,47,30,330/- (Rupees Thirty Six Crores Forty Seven Lakhs Thirty Thousand Three Hundred and Thirty only) divided into 18,23,65,165 equity shares of Rs.2/- each.</p> <p>With this allotment Natco Employees Stock Option Scheme NATSOP 2016 will be closed.</p>

Please find enclosed press release.

This is for your information and records.

Meeting commenced at 2.30 p.m. and concluded at 3.00 p.m.

Thanking you,  
Yours faithfully,  
For NATCO Pharma Limited

  
M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)  
Encl: a.a.

Annexure- I

**Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	<b>1) Name of the target entity</b>  Dash Pharmaceuticals LLC  <b>2) Details in brief such as size, turnover etc.</b>  Dash Pharmaceuticals LLC is engaged in the business of pharmaceuticals in USA. For the year ended December 31, 2020, the net revenue is US\$ 11.13 million.
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Pharmaceuticals
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To have a direct frontend marketing footprint in USA
E	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
F	Indicative time period for completion of the acquisition;	January 31, 2022
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration of US\$ 18 million
H	Cost of acquisition or the price at which the shares are acquired	US\$ 18 million for 100% acquisition
I	Percentage of shareholding / control acquired and / or number of shares acquired	100% control to be acquired through one of the Subsidiary Company

*M. Anurag*



Sl. No.	Particulars	Details of Investment
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><b>1. Brief background:</b></p> <p>Dash Pharmaceuticals LLC is in the business of selling pharmaceutical formulations in USA.</p> <p><b>2. Line of business:</b></p> <p>Pharmaceuticals</p> <p><b>3. Date of incorporation:</b></p> <p>June 3, 2014</p> <p><b>4. Turnover of last 3 years ending December 31 (in US\$):</b></p> <p>For the year 2020: 11,129,492  For the year 2019: 7,016,124  For the year 2018: 2,543,054</p> <p><b>5. Country in which the acquired entity has presence:</b></p> <p>United States of America</p>

*M. Anwar Saif*





# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/18/2021-2022

December 14, 2021

## Press Release

NATCO Pharma Limited through its affiliates is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC ("Dash") subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements. Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year ending December 2021.

This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.

Forwarded for favour of publication  
For NATCO Pharma Limited

A handwritten signature in blue ink, appearing to read "M Adinarayana".

M Adinarayana  
Company Secretary &  
V.P.(Legal & Corp Affairs)